3-indol substituted derivatives, pharmaceutical compositions and methods for use

Patent metadata

Field	Value
Publication number	US-9873690-B2
Application number	US-201615072534-A
Country	US
Kind code	B2
Filing date	Mar 17, 2016
Priority date	Mar 17, 2015
Publication date	Jan 23, 2018
Grant date	Jan 23, 2018

Abstract

A compound of Formula I is provided:

or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula I.

First claim

The invention claimed is:

1. A compound of formula I:

or a pharmaceutically acceptable enantiomer, salt, or solvate thereof, wherein:
X 1 and X 2 represent each independently H, halogen, OH, OR 7 ; or C1-C4 alkyl;
R 1 , R 2 , and R 3 are independently: H, halogen, cyano, R 7 , OR 7 , NR 7 R 8 , CONR 7 , N(R 7 )COR 8 , SO 2 R 7 , or alkylNR 7 R 8 ;
Q is H or COR 7 or CONR 7 R 8 ;
R 7 and R 8 are independently (i) H, (ii) NH 2 , (iii) C1 to C6 branched or unbranched alkyl, optionally substituted with one to three substituents selected from one or more of oxo, amino, OH, halogen, or C1 to C4 alkyl, (iv) a C1-C3 alkyl-heterocycle or (v) a heterocycle, wherein the heterocycle of (iv) or (v) is an optionally substituted five or six-membered heterocycle in which the substituent is oxo, OH, NH 2 , or a C1 to C3 alkyl which is optionally substituted with one to three substituents selected from one or more of a halogen, alkyl, OH, oxo, or amino;
A 1 and A 2 together form a 5-membered fused ring structure comprising SO 2 NR 5 CR 9′ R 9 , wherein R 9′ is H, or R 9′ and R 9 are each methyl, wherein when R 9′ is H, R 9 is a hydrogen atom, cyclopropyl, or a group, optionally substituted, selected from C1-C6 alkyl, aryl, arylalkyl, alkylaryl, heteroaryl, heteroarylalkyl, or alkylheteroaryl, wherein the optionally substituted group has one, two or three substituents selected from one or more of a halogen, C1-C4 alkyl, OH, oxo, or amino;
R 5 is: (i′) H, (ii′) oxo, (iii′) amino, or (iv′) a group, optionally substituted, selected from:
(v′) C1-C6 alkyl, linear or branched, optionally substituted with up to three substituents selected from one or more of halogen, hydroxyl, OR 9 , COOR 9 , CONR 9 R 10 , NR 9 COR 10 , NR 9 R 10 , SO 2 R 9 , SO 2 NR 9 R 10 , NR 9 SO 2 R 10 , SOR 9 , aryl, or CO-alkyl,
(vi′) heterocyclyl or C1-C3 alkyl-heterocyclyl, the heterocyclyl being optionally substituted with up to three substituents which are selected from one or more of halogen, hydroxyl, oxo, OR 9 , COOR 9 , CONR 9 R 10 , NR 9 COR 10 , NR 9 R 10 , SO 2 R 9 , SO 2 NR 9 R 10 , NR 9 SO 2 R 10 , SO 2 R 9 , aryl, CO-alkyl, a five or six membered heterocycle having 2 N atoms in its backbone; a piperidine substituted with F and three OH, or alkyl, the alkyl group being optionally substituted by one to three groups selected from one or more of halogen, hydroxyl, oxo, amino or COOH;
(vii′) cycloalkyl, optionally substituted with up to three substituents selected from halogen, hydroxyl, OR 9 , COOR 9 , CONR 9 R 10 , NR 9 COR 10 , NR 9 R 10 , SO 2 R 9 , SO 2 NR 9 R 10 , NR 9 SO 2 R 19 , SO 2 R 9 , aryl, CO-alkyl, or C1-C6 alkyl which is optionally substituted by one or more groups selected from halogen, hydroxyl, amino or COOH;
R 9 and R 10 represent each independently a hydrogen atom or a group, optionally substituted, selected from C1-C6 alkyl, wherein when substituted, the C1-C6 alkyl has one, two or three groups selected from one or more halogen, hydroxyl, oxo, amino or COOH, heterocyclyl, aryl, arylalkyl, alkylaryl, heteroaryl, heteroarylalkyl, or alkylheteroaryl, wherein when substituted, the aryl, arylalkyl, alkylaryl, heteroaryl, heteroarylalkyl, alkylheteroaryl has up to three substituents which are one or more of halogen, hydroxyl, oxo, OR 9 , COOR 9 , CONR 9 R 10 , NR 9 COR 10 , NR 9 R 10 , SO 2 R 9 , SO 2 NR 9 R 10 , NR 9 SO 2 R 10 , SO 2 R 9 , CO-alkyl, or amino.

2. The compound according to claim 1 , wherein Q is H.

3. The compound according to claim 1 , wherein X 1 and X 2 are independently H, F or Cl.

4. The compound according to claim 3 , wherein X 1 is H and X 2 is F.

5. The compound according to claim 1 , wherein R 5 is the C1-C3 alkyl-heterocyclyl optionally substituted with up to three substituents which are independently halogen, C1-C6 alkyl, hydroxyl, oxo, OR 9 , COOR 9 , CONR 9 R 10 , NR 9 COR 10 , NR 9 R 10 , SO 2 R 9 , SO 2 NR 9 R 10 , NR 9 SO 2 R 10 , SO 2 R 9 .

6. The compound according to claim 1 , wherein R 9 is a C1-C4 alkyl which is optionally substituted with OH or halogen.

7. The compound according to claim 1 , wherein the compound is not in salt form.

8. The compound according to claim 1 , wherein the compound is selected from the group consisting of:
(+)-5-(6-fluoro-1H-indol-3-yl)-3-methyl-2,3-dihydro-1,2-benzothiazole 1,1-dioxide, or
(−)-5-(6-fluoro-1H-indol-3-yl)-3-methyl-2,3-dihydro-1,2-benzothiazole 1,1-dioxide,
(+)-3-ethyl-5-(6-fluoro-1H-indol-3-yl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide,
(−)-3-ethyl-5-(6-fluoro-1H-indol-3-yl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide,
5-(6-fluoro-1H-indol-3-yl)-3,3-dimethyl-2,3-dihydrobenzo[d]-isothiazole 1,1-dioxide,
(+)-5-(6-fluoro-1H-indol-3-yl)-3-propyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide,
(−)-5-(6-fluoro-1H-indol-3-yl)-3-propyl-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide,
(+)-5-(6-fluoro-1H-indol-3-yl)-3-isopropyl-2,3-dihydrobenzo[d]-isothiazole 1,1-dioxide,
(−)-5-(6-fluoro-1H-indol-3-yl)-3-isopropyl-2,3-dihydrobenzo[d]-isothiazole 1,1-dioxide,
(+)-3-cyclopropyl-5-(6-fluoro-1H-indol-3-yl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide,
(−)-3-cyclopropyl-5-(6-fluoro-1H-indol-3-yl)-2,3-dihydrobenzo[d]iso-thiazole 1,1-dioxide,
(−)-5-(6-fluoro-1H-indol-3-yl)-3-(hydroxymethyl)-2,3-dihydrobenzo[d]-isothiazole 1,1-dioxide,
(+)-5-(6-fluoro-1H-indol-3-yl)-3-(hydroxymethyl)-2,3-dihydrobenzo[d]-isothiazole 1,1-dioxide,
methyl 5-(6-fluoro-1H-indol-3-yl)-2,3-dihydrobenzo[d]isothiazole-3-carboxylate 1,1-dioxide,
(−)-5-(6-fluoro-1H-indol-3-yl)-2,3-dihydrobenzo[d]isothiazole-3-carboxamide 1,1-dioxide,
(+)-5-(6-fluoro-1H-indol-3-yl)-2,3-dihydrobenzo[d]isothiazole-3-carboxamide 1,1-dioxide,
(−)-5-(6-fluoro-1H-indol-3-yl)-N-methyl-2,3-dihydrobenzo[d]-isothiazole-3-carboxamide 1,1-dioxide,
(+)-5-(6-fluoro-1H-indol-3-yl)-N-methyl-2,3-dihydrobenzo[d]-isothiazole-3-carboxamide 1,1-dioxide,
(+)-3-(aminomethyl)-5-(6-fluoro-1H-indol-3-yl)-2,3-dihydrobenzo[d]-isothiazole 1,1-dioxide,
(−)-3-(aminomethyl)-5-(6-fluoro-1H-indol-3-yl)-2,3-dihydrobenzo[d]-isothiazole 1,1-dioxide,
(−)-methyl((5-(6-fluoro-1H-indol-3-yl)-1,1-dioxido-2,3-dihydro-benzo[d]isothiazol-3-yl)methyl)carbamate,
(+)-methyl((5-(6-fluoro-1H-indol-3-yl)-1,1-dioxido-2,3-dihydro-benzo[d]isothiazol-3-yl)methyl)carbamate,
(−)-N-((5-(6-fluoro-1H-indol-3-yl)-1,1-dioxido-2,3-dihydro-benzo[d]isothiazol-3-yl)methyl)acetamide,
(+)-N-((5-(6-fluoro-1H-indol-3-yl)-1,1-dioxido-2,3-dihydro-benzo[d]isothiazol-3-yl)methyl)acetamide,
(−)-3-((dimethylamino)methyl)-5-(6-fluoro-1H-indol-3-yl)-2,3-dihydro-benzo[d]isothiazole 1,1-dioxide,
(+)-3-((dimethylamino)methyl)-5-(6-fluoro-1H-indol-3-yl)-2,3-dihydro-benzo[d]isothiazole 1,1-dioxide,
(+)-N-((5-(6-fluoro-1H-indol-3-yl)-1,1-dioxido-2,3-dihydro-benzo[d]isothiazol-3-yl)methyl)-N-methylacetamide,
(−)-N-((5-(6-fluoro-1H-indol-3-yl)-1,1-dioxido-2,3-dihydro-benzo[d]isothiazol-3-yl)methyl)-N-methylacetamide,
(−)-5-(6-fluoro-1H-indol-3-yl)-3-(2-hydroxyethyl)-2,3-dihydro-benzo[d]isothiazole 1,1-dioxide,
(+)-5-(6-fluoro-1H-indol-3-yl)-3-(2-hydroxyethyl)-2,3-dihydro-benzo[d]isothiazole 1,1-dioxide,
2-(2-aminoethyl)-5-(6-fluoro-1H-indol-3-yl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide,
2-(2-(dimethylamino)ethyl)-5-(6-fluoro-1H-indol-3-yl)-2,3-dihydro-benzo[d]isothiazole 1,1-dioxide,
5-(6-fluoro-1H-indol-3-yl)-2-(2-hydroxyethyl)-2,3-dihydro-benzo[d]isothiazole 1,1-dioxide,
(S)-2-(2,3-dihydroxypropyl)-5-(6-fluoro-1H-indol-3-yl)-2,3-dihydro-benzo[d]isothiazole 1,1-dioxide,
(R)-2-(2,3-dihydroxypropyl)-5-(6-fluoro-1H-indol-3-yl)-2,3-dihydro-benzo[d]isothiazole 1,1-dioxide,
5-(6-fluoro-1H-indol-3-yl)-2-(piperidin-4-yl)-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide,
5

Assignees

• Pfizer
• Iteos Therapeutics
• Pfizer

Inventors

• Ninkovic Sacha
• Crosignani Stefano
• Mcalpine Indrawan James
• Collins Michael Raymond
• Scales Stephanie Anne
• Maderna Andreas
• Wythes Martin

Classifications

• A61P31/18

  for HIV · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/12

  Antivirals · CPC title